These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells. Mahan SD; Riching KM; Urh M; Daniels DL Methods Mol Biol; 2021; 2365():151-171. PubMed ID: 34432243 [TBL] [Abstract][Full Text] [Related]
4. Advancing targeted protein degrader discovery by measuring cereblon engagement in cells. Zerfas BL; Huerta F; Liu H; Du G; Gray NS; Jones LH; Nowak RP Methods Enzymol; 2023; 681():169-188. PubMed ID: 36764756 [TBL] [Abstract][Full Text] [Related]
5. Discovery of E3 Ligase Ligands for Target Protein Degradation. Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052 [TBL] [Abstract][Full Text] [Related]
6. Target protein localization and its impact on PROTAC-mediated degradation. Simpson LM; Glennie L; Brewer A; Zhao JF; Crooks J; Shpiro N; Sapkota GP Cell Chem Biol; 2022 Oct; 29(10):1482-1504.e7. PubMed ID: 36075213 [TBL] [Abstract][Full Text] [Related]
7. An In Vitro Pull-down Assay of the E3 Ligase:PROTAC:Substrate Ternary Complex to Identify Effective PROTACs. Bondeson DP; Smith BE; Buhimschi AD Methods Mol Biol; 2021; 2365():135-150. PubMed ID: 34432242 [TBL] [Abstract][Full Text] [Related]
8. Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes. Zhang L; Riley-Gillis B; Vijay P; Shen Y Mol Cancer Ther; 2019 Jul; 18(7):1302-1311. PubMed ID: 31064868 [TBL] [Abstract][Full Text] [Related]
9. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones. Ishida T; Ciulli A SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537 [TBL] [Abstract][Full Text] [Related]
10. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs. Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445 [TBL] [Abstract][Full Text] [Related]
11. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders. Yang K; Zhao Y; Nie X; Wu H; Wang B; Almodovar-Rivera CM; Xie H; Tang W Cell Chem Biol; 2020 Jul; 27(7):866-876.e8. PubMed ID: 32413286 [TBL] [Abstract][Full Text] [Related]
12. Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach. Chen Q; Liu C; Wang W; Meng X; Cheng X; Li X; Cai L; Luo L; He X; Qu H; Luo J; Wei H; Gao S; Liu G; Wan J; Israel DI; Li J; Dou D ACS Chem Biol; 2023 Jan; 18(1):25-33. PubMed ID: 36606710 [TBL] [Abstract][Full Text] [Related]
14. Proteolysis-targeting chimeras (PROTACs) in cancer therapy. Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300 [TBL] [Abstract][Full Text] [Related]
15. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718 [TBL] [Abstract][Full Text] [Related]
16. Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention. Singh H; Agrawal DK Future Med Chem; 2022 Oct; 14(19):1403-1416. PubMed ID: 36047364 [TBL] [Abstract][Full Text] [Related]
17. Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry. Guo WH; Qi X; Yu X; Liu Y; Chung CI; Bai F; Lin X; Lu D; Wang L; Chen J; Su LH; Nomie KJ; Li F; Wang MC; Shu X; Onuchic JN; Woyach JA; Wang ML; Wang J Nat Commun; 2020 Aug; 11(1):4268. PubMed ID: 32848159 [TBL] [Abstract][Full Text] [Related]